INSM - Insmed - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4576693075

Antibacterial, Inhibitor, Inhalation Powder

Insmed Incorporated is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for patients with serious and rare diseases.

The company has already made a significant impact with its flagship product, ARIKAYCE, which is used to treat Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. This treatment has brought hope to many patients suffering from this debilitating disease.

In addition to ARIKAYCE, Insmed is also working on several promising pipeline projects, including Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1. This potential treatment is being developed to help patients with bronchiectasis and other neutrophil-mediated diseases, offering a new avenue for managing these complex conditions.

Another area of focus for Insmed is the development of Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil. This innovative treatment is being developed to address pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension, providing a potential solution for patients struggling with these life-threatening conditions.

With a rich history dating back to 1988, Insmed Incorporated is headquartered in Bridgewater, New Jersey, and continues to drive innovation in the biopharmaceutical industry. For more information about the company and its mission, visit their website at https://www.insmed.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for INSM - Insmed  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for INSM - Insmed  - Stock Price & Dividends

INSM Stock Overview

Market Cap in USD 11,418m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2000-06-01

INSM Stock Ratings

Growth 5y 38.4
Fundamental -54.8
Dividend -
Rel. Performance vs Sector 8.73
Analysts 4.69/5
Fair Price Momentum 83.34 USD
Fair Price DCF -

INSM Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

INSM Growth Ratios

Growth 12m 252.56%
Growth Correlation 12m 47%
Growth Correlation 3m 75%
CAGR 5y 28.12%
CAGR/Mean DD 5y 0.81
Sharpe Ratio 12m 1.96
Alpha vs SP500 12m 220.56
Beta vs SP500 5y weekly 1.44
ValueRay RSI 72.39
Volatility GJR Garch 1y 50.83%
Price / SMA 50 39.1%
Price / SMA 200 123.39%
Current Volume 2390.7k
Average Volume 20d 3133.4k

External Links for INSM Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of INSM stocks?
As of July 19, 2024, the stock is trading at USD 75.06 with a total of 2,390,655 shares traded.
Over the past week, the price has changed by -2.56%, over one month by +14.46%, over three months by +202.66% and over the past year by +256.07%.
What are the forecast for INSM stock price target?
According to ValueRays Forecast Model, INSM Insmed will be worth about 93.1 in July 2025. The stock is currently trading at 75.06. This means that the stock has a potential upside of +24.07%.
Issuer Forecast Upside
Wallstreet Target Price 76.3 1.61
Analysts Target Price 42.6 -43.3
ValueRay Target Price 93.1 24.1